Welcome to our dedicated page for COGNEX SEC filings (Ticker: CGNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cognex Corporation filings document regulatory disclosures for an operating company focused on industrial machine vision products and automation technology. Its Form 8-K reports cover furnished operating results, quarterly cash dividends, share repurchase authorization, board and officer matters, annual meeting voting results, and changes in the company’s independent registered public accounting firm.
Proxy materials describe director elections, governance matters, executive compensation, shareholder voting procedures, and board committee oversight. The filing record also includes exhibit-based disclosures tied to financial-results releases and capital-return actions involving Cognex common stock.
Cognex delivered significantly stronger results in Q2 2026, with revenue of $291,263,000, up 17% year over year, and gross margin improving to 71% from 67%. Operating income rose to $85,517,000 (29% of revenue), and net income reached $72,756,000, or $0.43 per diluted share.
For the first half of 2026, revenue grew 20% to $559,700,000 and net income was $124,460,000, supported by broad-based demand, especially in Greater China and the Americas, while Europe was softer. Cognex held $755,013,000 in cash and investments with no long‑term debt, generated $114,246,000 of operating cash flow, repurchased 2,501,000 shares for $105,231,000, and paid dividends totaling $28,454,000 in six months.
Cognex Corporation reported a strong second quarter for the period ended July 5, 2026. Revenue reached a record $291 million, up 17% year over year (16% in constant currency), with operating income of $86 million and an operating margin of 29.4%. Adjusted EBITDA was $94 million, for a margin of 32.2%, while net income was $73 million and diluted EPS was $0.43; adjusted diluted EPS was $0.45, up 80% year over year.
Gross margin improved to 70.6%, and operating expenses declined 3% versus the prior year quarter, supporting the eighth consecutive quarter of margin expansion. Cognex ended the quarter with $755 million in cash and investments and no debt, generated $69 million in operating cash flow and $68 million in free cash flow, and paid $14 million in dividends.
The company issued guidance for third-quarter 2026 revenue of $300–$320 million and full-year 2026 revenue of $1.13–$1.15 billion, with higher adjusted EBITDA margins and adjusted EPS versus 2025. Cognex also declared a quarterly dividend of $0.085 per share and highlighted the general availability of its OneVision™ AI-powered machine vision platform.
CGNX files a Form 144 reporting proposed sales of common stock by an affiliate. The filing lists 172,667 shares to be sold on 06/30/2026 in connection with a stock option exercise for cash. The filing also discloses three sales by Robert J. Willett totaling listed share amounts within the prior three months.
CGNX files a Rule 144 notice reporting the intended sale of 8,576 shares of Common Stock via a stock option exercise on 06/29/2026.
The notice lists prior sales during the past three months: 53,726 shares sold on 05/06/2026 for $3,312,316.58 and 423,478 shares sold on 05/07/2026 for $28,831,493.28. The broker listed is Fidelity Brokerage Services LLC.
Cognex Corp vice president Darren Marc Long reported a combination of option exercises and share sales in company stock. On May 27, 2026, he exercised non-qualified stock options covering 18,673 shares of common stock at strike prices of $49.12, $51.49, and $56.44 per share.
On the same date, he completed open-market sales totaling 20,252 shares of common stock at prices of $66.5201 and $66.3215 per share. After these transactions, Long directly held 5,569 shares of Cognex common stock. The filing also lists prior grants of stock options and restricted stock units as part of his ongoing equity compensation.
Morgan Stanley Smith Barney LLC filed a Form 144 reporting the proposed sale of Common Stock of CGNX tied to a stock option exercise for 18,673 shares scheduled on 05/27/2026. The filing also lists prior restricted stock grants dated 02/16/2022, 02/16/2023, and 02/18/2023 with 145, 216, and 1,218 shares respectively.
CGNX amended a Form 144/A reporting proposed and recent transactions in Common Stock, including multiple settled Restricted Stock Unit releases, several option grant tranches and a recent sale. The filing lists a sale of 14,881 shares for $850,554 on 02/12/2026 by Laura Ann MacDonald.
The amendment enumerates RSU settlements dated 02/22/2024, 02/22/2023, 02/16/2023, 02/16/2022, and multiple option grants with per‑grant share counts shown as examples; timing and cash‑flow treatment are those recorded in the entries.
COGNEX CORP Chief Legal Officer & Secretary Mark Fennell reported a series of option exercises and related share sales in Common Stock. On May 11, 2026, he exercised options to acquire a total of 60,010 shares at exercise prices ranging from $33.04 to $56.44 per share. On the same date, he executed open-market sales totaling 64,873 shares at prices including $66.73 and $67.08 per share. Following these transactions, Fennell directly holds 4,863 shares of Cognex Common Stock. Footnotes describe prior option grants that vest in annual installments over several years.
Cognex Corp VP and PAO Laura Ann Macdonald reported a series of option exercises paired with open‑market sales of Common Stock on May 11–12, 2026. She sold a total of 139,722 shares of Common Stock in open‑market transactions at prices including $66.8022 and $65.5632 per share.
These sales followed exercises of stock options covering 137,510 shares at strike prices ranging from $33.04 to $56.44 per share. After the transactions, she holds 5,258 Common shares directly, plus equity awards such as Restricted Stock Units and Non‑Qualified Stock Options, including 11,211 RSUs and options for 23,891 shares at an exercise price of $64.43. An additional 20 shares are held indirectly by her child, for which she disclaims beneficial ownership except for any pecuniary interest.
CGNX reported proposed sales of common stock under Rule 144 and disclosed recent dispositions. The notice lists intended sales of 6,100, 10,000 and 25,500 shares tied to option grants, and two completed dispositions in the past three months of 14,881 shares for $850,554.00 and 98,122 shares for $6,554,765.00.
The filing identifies the transactions as issuer-related option exercises and records the broker as Robert W Baird & Co on 05/12/2026. Timing and cash‑flow treatment for the planned sales are shown as 05/12/2026.